Park Avenue Securities LLC Buys 204 Shares of Lantheus Holdings, Inc. (NASDAQ:LNTH)

Park Avenue Securities LLC grew its stake in shares of Lantheus Holdings, Inc. (NASDAQ:LNTH) by 8.3% during the 1st quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 2,662 shares of the medical equipment provider’s stock after buying an additional 204 shares during the period. Park Avenue Securities LLC’s holdings in Lantheus were worth $260,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Several other institutional investors and hedge funds have also recently modified their holdings of the stock. UMB Bank n.a. grew its holdings in shares of Lantheus by 68.2% in the first quarter. UMB Bank n.a. now owns 940 shares of the medical equipment provider’s stock valued at $92,000 after purchasing an additional 381 shares in the last quarter. Procyon Advisors LLC boosted its stake in Lantheus by 22.5% during the first quarter. Procyon Advisors LLC now owns 4,426 shares of the medical equipment provider’s stock worth $432,000 after buying an additional 813 shares during the period. Silverberg Bernstein Capital Management LLC increased its position in Lantheus by 5.0% during the first quarter. Silverberg Bernstein Capital Management LLC now owns 21,129 shares of the medical equipment provider’s stock valued at $2,062,000 after acquiring an additional 1,000 shares during the last quarter. Rhumbline Advisers increased its position in Lantheus by 1.7% during the first quarter. Rhumbline Advisers now owns 216,296 shares of the medical equipment provider’s stock valued at $21,110,000 after acquiring an additional 3,623 shares during the last quarter. Finally, Fifth Third Wealth Advisors LLC bought a new position in Lantheus during the first quarter valued at $207,000. Institutional investors own 99.06% of the company’s stock.

Analyst Upgrades and Downgrades

A number of research analysts have weighed in on the stock. B. Riley cut their price objective on shares of Lantheus from $127.00 to $122.00 and set a “buy” rating on the stock in a research report on Friday, March 21st. Truist Financial lowered their target price on shares of Lantheus from $127.00 to $117.00 and set a “buy” rating for the company in a research note on Thursday, May 8th. Finally, Wall Street Zen raised shares of Lantheus from a “hold” rating to a “buy” rating in a research note on Thursday, May 8th. Seven analysts have rated the stock with a buy rating, According to MarketBeat, the stock currently has a consensus rating of “Buy” and an average price target of $132.67.

Insider Buying and Selling at Lantheus

In other Lantheus news, Director Mary Anne Heino sold 26,066 shares of the stock in a transaction dated Monday, June 2nd. The shares were sold at an average price of $76.83, for a total transaction of $2,002,650.78. Following the completion of the sale, the director now directly owns 318,650 shares of the company’s stock, valued at approximately $24,481,879.50. This represents a 7.56% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which can be accessed through this hyperlink. Insiders own 1.50% of the company’s stock.

Lantheus Price Performance

NASDAQ:LNTH opened at $77.83 on Monday. Lantheus Holdings, Inc. has a 1-year low of $73.11 and a 1-year high of $126.89. The company has a 50-day moving average of $88.82 and a 200 day moving average of $91.40. The firm has a market cap of $5.38 billion, a PE ratio of 12.95 and a beta of 0.11.

Lantheus (NASDAQ:LNTH) last released its quarterly earnings data on Wednesday, May 7th. The medical equipment provider reported $1.53 earnings per share for the quarter, missing analysts’ consensus estimates of $1.64 by ($0.11). Lantheus had a return on equity of 44.29% and a net margin of 28.57%. The business had revenue of $372.76 million during the quarter, compared to analysts’ expectations of $377.37 million. During the same period last year, the company earned $1.69 earnings per share. The firm’s revenue was up .8% compared to the same quarter last year. Sell-side analysts anticipate that Lantheus Holdings, Inc. will post 6.01 EPS for the current fiscal year.

Lantheus Company Profile

Lantheus Holdings, Inc develops, manufactures, and commercializes diagnostic and therapeutic products that assist clinicians in the diagnosis and treatment of heart, cancer, and other diseases worldwide. It provides DEFINITY, an injectable ultrasound enhancing agent used in echocardiography exams; TechneLite, a technetium generator for nuclear medicine procedures; Xenon-133, a radiopharmaceutical gas to assess pulmonary function; Neurolite, an injectable imaging agent to identify the area within the brain where blood flow has been blocked or reduced due to stroke; Cardiolite, an injectable Tc-99m-labeled imaging agent to assess blood flow to the muscle of the heart; and PYLARIFY, an F 18-labelled PSMA-targeted PET imaging agent used for imaging of PSMA positive-lesions in men with prostate cancer.